Management said it is repositioning toward a biotechnology platform focused on stem cells and regenerative medicine, with AI and digital tools supporting research and precision-health applications.
First-half results and balance sheet
Visionary Holdings posted first-half fiscal 2026 revenue of about US$434,648.
Net loss attributable to shareholders narrowed to about US$2 million from about US$5.9 million a year earlier.
Gross profit totaled about US$283,961, yielding a 65.3% gross margin.
Total assets stood at about US$65.7 million at period end, with results still reflecting existing operations as biotech initiatives remain in development.
GV•
